journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Drug Safety

journal
https://www.readbyqxmd.com/read/29318007/severe-haematuria-of-lower-urinary-tract-origin-with-low-dose-dabigatran-use-in-three-indian-elderly-patients-unresolved-issues-in-the-safety-of-novel-oral-anticoagulants
#1
Upinder Kaur, Sankha Shubhra Chakrabarti, Sukdev Manna, Indrajeet Singh Gambhir
Dabigatran is a newer oral direct thrombin inhibitor approved by the United States Food and Drug Administration and the European Medicines Agency (EMA). The proper dosage of the drug, the potential for adverse drug reactions and the nature of bleeds with use of this drug as with other novel oral anticoagulants (NOACs), in the elderly population are still areas of uncertainty. Despite the existence of a specific antibody, idarucizumab which is an antidote to dabigatran toxicity, management of dabigatran-induced bleeds is an undefined area especially in resource constrained settings...
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29318006/naloxone-dosage-for-opioid-reversal-current-evidence-and-clinical-implications
#2
REVIEW
Rachael Rzasa Lynn, J L Galinkin
Opioid-related mortality is a growing problem in the United States, and in 2015 there were over 33,000 opioid-related deaths. To combat this mortality trend, naloxone is increasingly being utilized in a pre-hospital setting by emergency personnel and prescribed to laypersons for out-of-hospital administration. With increased utilization of naloxone there has been a subsequent reduction in mortality following an opioid overdose. Reversal of opioid toxicity may precipitate an opioid-withdrawal syndrome. At the same time, there is a risk of inadequate response or re-narcotization after the administration of a single dose of naloxone in patients who have taken large doses or long-acting opioid formulations, as the duration of effect of naloxone is shorter than that of many opioid agonists...
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29318005/precision-medicine-does-ethnicity-information-complement-genotype-based-prescribing-decisions
#3
REVIEW
Rashmi R Shah, Andrea Gaedigk
Inter-ethnic differences in drug response are all too well known. These are underpinned by a number of factors, including pharmacogenetic differences across various ethnic populations. Precision medicine relies on genotype-based prescribing decisions with the aim of maximizing efficacy and mitigating the risks. When there is no access to genotyping tests, ethnicity is frequently regarded as a proxy of the patient's probable genotype on the basis of overall population-based frequency of genetic variations in the ethnic group the patient belongs to, with some variations being ethnicity-specific...
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29318004/poly-de-prescribing-to-treat-polypharmacy-efficacy-and-safety
#4
Doron Garfinkel
Background: The aim of this study was to evaluate efficacy and safety of poly-de-prescribing (PDP) based on the Garfinkel method in older people with polypharmacy. Methods: A longitudinal, prospective, nonrandomized study in Israel was carried out between 2009 and 2016. Comprehensive geriatric assessments were performed at home in people age ⩾66 years consuming ⩾6 prescription drugs. Exclusion criteria were life expectancy <6 months and a seeming unwillingness to cooperate (poor compliance)...
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29318003/incident-adverse-drug-reactions-in-geriatric-inpatients-a-multicentred-observational-study
#5
Amanda Lavan, Joseph Eustace, Darren Dahly, Evelyn Flanagan, Paul Gallagher, Shane Cullinane, Mirko Petrovic, Katrina Perehudoff, Adalsteinn Gudmondsson, Ólafur Samuelsson, Ástrós Sverrisdóttir, Antonio Cherubin, Frederica Dimitri, Joe Rimland, Alfonso Cruz-Jentoft, Manuel Vélez-Díaz-Pallarés, Isabel Lozano Montoya, Roy L Soiza, Selvarani Subbarayan, Denis O'Mahony
Background: Adverse drug reactions (ADRs) are common in older adults and frequently have serious clinical and economic consequences. This study was conducted as a feasibility study for a randomized control trial (RCT) that will investigate the efficacy of a software engine to optimize medications and reduce incident (in-hospital) ADRs. This study's objectives were to (i) establish current incident ADR rates across the six sites participating in the forthcoming RCT and (ii) assess whether incident ADRs are predictable...
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29318002/the-hope-hype-and-reality-of-big-data-for-pharmacovigilance
#6
EDITORIAL
Andrew Bate, Robert F Reynolds, Patrick Caubel
No abstract text is available yet for this article.
January 2018: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29204267/tamsulosin-induced-diarrhea-a-case-report
#7
Arunkumar D Rana, Kinjal Dodiya, Manish J Barvaliya, Sameer Shah, Bhargav M Purohit, Chandrabhanu Rajkishor Tripathi
No abstract text is available yet for this article.
December 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29204266/pegloticase-in-gout-treatment-safety-issues-latest-evidence-and-clinical-considerations
#8
REVIEW
Allison Guttmann, Svetlana Krasnokutsky, Michael H Pillinger, Adey Berhanu
Gout is a common rheumatic condition, with increasing prevalence in recent decades. The mainstay of treatment for gout is oral urate-lowering therapy (ULT), typically with xanthine oxidase inhibitors (XOIs). Unfortunately, a proportion of patients have persistent gout that is refractory to ULT. Pegloticase, a recombinant pegylated uricase, has been approved by the US Food and Drug Administration for the treatment of refractory gout. However, concern has been raised regarding the risk of infusion reactions, which are now understood to be largely due to the development of antipegloticase antibodies...
December 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29204265/using-deep-learning-to-improve-medication-safety-the-untapped-potential-of-social-media
#9
EDITORIAL
Jiaheng Xie, Daniel Dajun Zeng, Zachary A Marcum
No abstract text is available yet for this article.
December 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29090085/assessing-and-predicting-drug-induced-anticholinergic-risks-an-integrated-computational-approach
#10
Dong Xu, Heather D Anderson, Aoxiang Tao, Katia L Hannah, Sunny A Linnebur, Robert J Valuck, Vaughn L Culbertson
BACKGROUND: Anticholinergic (AC) adverse drug events (ADEs) are caused by inhibition of muscarinic receptors as a result of designated or off-target drug-receptor interactions. In practice, AC toxicity is assessed primarily based on clinician experience. The goal of this study was to evaluate a novel concept of integrating big pharmacological and healthcare data to assess clinical AC toxicity risks. METHODS: AC toxicity scores (ATSs) were computed using drug-receptor inhibitions identified through pharmacological data screening...
November 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29090084/non-medical-prescribing-in-new-zealand-an-overview-of-prescribing-rights-service-delivery-models-and-training
#11
REVIEW
Rakhee Raghunandan, June Tordoff, Alesha Smith
AIM: In this paper, we aim to provide an updated source of information for nonmedical prescribing (NMP) in New Zealand (NZ). METHODS: A variety of NZ sources were used to collect data: legislation, policy documents and information from professional and regulatory organizations, and education providers. RESULTS: In NZ, the legal categories for prescribers include authorized, designated, and delegated prescribers. Authorized prescribers include dentists, midwives, nurse practitioners, and optometrist prescribers...
November 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/29090083/gastrointestinal-adverse-effects-of-cyclin-dependent-kinase-4-and-6-inhibitors-in-breast-cancer-patients-a-systematic-review-and-meta-analysis
#12
REVIEW
Kyrillus S Shohdy, Shaimaa Lasheen, Loay Kassem, Omar Abdel-Rahman
BACKGROUND: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors show promising results in metastatic breast cancer. However, an increased incidence of adverse events is remarkable. Among others, gastrointestinal (GI) involvement is of momentous impact on patients and their quality of life. METHODS: Our search included PubMed, ASCO, ESMO and SABCS databases. Randomized phase II/III trials in metastatic breast cancer receiving CDK4/6 inhibitors were identified and considered relevant based on providing a sufficient safety profile on the incidence of adverse GI effects...
November 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/28861212/revised-disproportionality-analysis-of-mirena-and-benign-intracranial-hypertension
#13
Mahyar Etminan
No abstract text is available yet for this article.
September 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/28861211/adverse-effects-of-proton-pump-inhibitor-use-in-older-adults-a-review-of-the-evidence
#14
REVIEW
Marina L Maes, Danielle R Fixen, Sunny Anne Linnebur
Proton-pump inhibitors (PPIs) are a widely prescribed class of medications used to treat acid-related disorders and use has significantly increased over the last few decades. PPIs are often inappropriately prescribed and since they have been on the market, a number of post-marketing studies have been published demonstrating associations between longer duration of PPI therapy and a number of adverse effects that are a concern in older adults. The objective of this review is to discuss the existing literature of potential adverse effects with long-term PPI use in older adults and to summarize the implications in clinical practice...
September 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/28861210/pharmacogenetics-and-precision-medicine-is-inflammation-a-covert-threat-to-effective-genotype-based-therapy
#15
EDITORIAL
Rashmi R Shah
No abstract text is available yet for this article.
September 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/28781738/digital-necrosis-a-potential-risk-of-high-dose-norepinephrine
#16
Rafael Daroca-Pérez, Miguel F Carrascosa
No abstract text is available yet for this article.
August 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/28781737/multidrug-intolerance-in-the-treatment-of-hypertension-result-from-an-audit-of-a-specialized-hypertension-service
#17
Basil N Okeahialam
BACKGROUND: Hypertension as a cardiovascular disease risk factor continues to take a heavy toll on the population despite efforts with containment. Poor control, even among those on treatment, is part of the challenge and results from patient, physician and health system factors. When the problem resides at patient level, adherence is largely responsible. An entity defined as multidrug intolerance (MDI) is hardly considered. A situation when a patient is willing to adhere but is compelled otherwise could frustrate both patient and physician...
August 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/28845232/solifenacin-linked-qt-interval-prolongation-and-torsades-de-pointes
#18
Jonathan J H Bray, Jules C Hancox
No abstract text is available yet for this article.
July 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/28845231/a-mathematical-framework-to-quantify-the-masking-effect-associated-with-the-confidence-intervals-of-measures-of-disproportionality
#19
François Maignen, Manfred Hauben, Jean-Michel Dogné
BACKGROUND: The lower bound of the 95% confidence interval of measures of disproportionality (Lower95CI) is widely used in signal detection. Masking is a statistical issue by which true signals of disproportionate reporting are hidden by the presence of other medicines. The primary objective of our study is to develop and validate a mathematical framework for assessing the masking effect of Lower95CI. METHODS: We have developed our new algorithm based on the masking ratio (MR) developed for the measures of disproportionality...
July 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/28845230/screening-for-valve-disease-in-patients-with-hyperprolactinaemia-disorders-prescribed-cabergoline-a-service-evaluation-and-literature-review
#20
REVIEW
David Gamble, Rachel Fairley, Roderick Harvey, Colin Farman, Nathan Cantley, Stephen J Leslie
OBJECTIVES: The indication for screening for valvular heart disease in patients taking cabergoline is based on evidence from patients with Parkinson's disease on high-dose medication. However, current patients take much lower doses for indications such as hyperprolactinaemia disorders. Contemporary guidelines for echocardiogram monitoring in patients taking cabergoline are conflicting. This study aimed to review current clinical practice in our area regarding echocardiographic screening and to review the literature examining the evidence of valvular heart disease in patients taking lower dose cabergoline...
July 2017: Therapeutic Advances in Drug Safety
journal
journal
43349
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"